Mannan-binding lectin: clinical significance and applications.


Mannan-binding lectin (MBL) is a collectin (protein with both collagen-like and C-type lectin domains) synthesised in the liver and secreted into the bloodstream. Its plasma concentration is for the most part genetically determined by a series of allelic dimorphisms located both in the structural gene and in the promoter region. Genotypes made up of combinations of seven haplotypes are mainly responsible for a 1000-fold concentration variation found in human beings. MBL is a pattern recognition molecule able to bind repeating sugar arrays on many microbial surfaces, and can activate complement via associated serine proteases. A poorly defined proportion (roughly 10%) of the population with the lowest MBL concentrations is thought to be MBL insufficient and more vulnerable to a variety of infectious and noninfectious disorders. The evidence that MBL makes an important contribution to innate immunity, by increasing susceptibility to disease and/or affecting the course of disease, is discussed in detail. Preliminary results from MBL replacement therapy are encouraging, and extension of this approach to large-scale randomised clinical trials would provide solid evidence concerning the physiological significance of this protein.

Citations per Year

3,200 Citations

Semantic Scholar estimates that this publication has 3,200 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Kilpatrick2002MannanbindingLC, title={Mannan-binding lectin: clinical significance and applications.}, author={David Kilpatrick}, journal={Biochimica et biophysica acta}, year={2002}, volume={1572 2-3}, pages={401-13} }